The Role of the Pharmacist in Hematologic Malignancies

MENA

$0

gratuit

SCFHS

2 hr

Oncologie

1.0 Credits

This course is expired! Browse All Courses
APPRENDRE ENCORE PLUS

Description du cours

The incidence of hematologic malignancies (leukemias, lymphomas and myelomas) in the Kingdom of Saudi Arabia (KSA) is on the rise. For example, according to the Saudi Cancer Registry, leukemia was the 5th most common cancer diagnosed in both genders between the years of 1999-2013. Hodgkin’s lymphoma accounts for 3.6% of all cancers in KSA and is the 7th most common cancer in Saudi males and the 8th most common cancer in Saudi females.

The objective of this online program is to help educate and support pharmacists in KSA in understanding the current landscape of leukemias, lymphomas, and myelomas, including current Saudi guidelines for selected malignancies.

This program is supported by Novartis.

Détails du cours

Date d'expiration : 2024-07-26

Métiers: Pharmacy, Specialist

Faculté

Dr. Riad al Fakih

Nora Alkhudair, reviewer

Accréditation

This program is accredited by the Saudi Commission for Health Specialties for 1.0 CPD Hour(s). 
Activity Accreditation Number: ACA-20230002487. 

Credits are reported to the Saudi Commission for Health Specialties on a monthly basis. Please ensure that your Saudi Commission ID is accurate in your profile and allow sufficient time for credits to appear in your Mustamir account.

This program is approved for the following professions: Laboratory‐Biochemistry, Radiotherapy, Nuclear Medicine, Hematology, Medical Oncology, Nuclear Medicine, Radiation Oncology, Hematological Pathology, Pharmaceutical Sciences, Clinical Pharmacy, Pharmaceutical administration and outcomes, Pharmacy.

Objectif(s) d'apprentissage

Upon completion of this continuing education program, participants will be better able to:

  • Décrire
     disease burden, risk factors, signs and symptoms
    and treatment for
    leukemias.
  • Décrire
    disease burden, risk factors, signs and symptoms
    and treatment for lymphomas.
  • Décrire
    disease burden, risk factors, signs and symptoms
    and treatment
    for myelomas.
  • Explain
    the role of the pharmacist in
    promoting optimal patient outcomes in
    hematologic malignancies.
This course is expired! Browse All Courses